Two River

We work with experienced teams to build outstanding companies that improve health outcomes and quality of life. At Two River we tailor our approach to the needs of each opportunity, partnering with management to create, finance or operate development-stage companies in the life sciences and healthcare sectors. Two River invests in companies with strong intellectual property and proven leadership teams who have demonstrated prior success developing innovative technologies in the life sciences sector. Two River is uniquely positioned to understand and balance the needs of the finance and life science communities. Our experience building companies spans a range of industry sectors including oncology, cardiovascular disease, ophthalmology, neurological disorders and animal health. We consider each of our investments to be a partnership, often working closely with portfolio companies on product development, regulatory and corporate strategy as well as day-to-day business operations.

Arie Belldegrun

Chairman and Partner

20 past transactions

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Kite Pharma, Inc.

Series A in 2013
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Cell Design Labs, Inc.

Venture Round in 2016
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability

Kite Pharma, Inc.

Series A in 2011
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

ByHeart

Series B in 2021
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Hubble Contacts

Seed Round in 2016
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.

Willow

Seed Round in 2018
Willow is stylish affordable disposable underwear that offers comfort, confidence, and leak-free protection, delivered discreetly to your door at a fraction of the price. Current options on the market are either expensive or bulky and generally lacking in style — plus, you have to purchase them at the store. Willow’s product is the thinnest and most absorbent on the market, and has better odor control than other products. It’s extremely "breathable” and wicks liquid away from skin, just like sportswear. Best of all, Willow’s stylish products cost less than others because they are sold directly to the consumer, with no mark up by stores.

Allogene Therapeutics Inc

Series A in 2018
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.

ByHeart

Series A in 2020
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Hubble Contacts

Seed Round in 2016
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.

Thirty Madison, Inc.

Series A in 2018
Thirty Madison, Inc., a digital health company, owns and operates web-based platforms for patients with hair loss, migraines, and other chronic conditions. It offers Keeps, a subscription-based online marketplace for over-the-counter medications for men’s hair loss prevention. The company also provides Cove, an online doctor visit and prescription service to treat migraine. In addition, it offers Evens that helps to treat acid reflux. Thirty Madison, Inc. was incorporated in 2016 and is headquartered in Astoria, New York.

Keeps

Series A in 2018
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

UroGen Pharma

Series A in 2015
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company’s lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.

Hubble Contacts

Venture Round in 2018
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.

IconOVir Bio

Series A in 2021
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Andie Co.

Seed Round in 2018
Andie is a designer and manufacturer of one-piece women’s swimsuits and sells them to consumers through its eCommerce platform. Its products are offered as a direct-to-consumer brand that cuts out retails middlemen and enables women to browse and buy designer-quality swimwear at accessible prices that they can try and home and find which one fits them best. By offering women high-design, luxurious swimsuits at an accessible price point, Andie provides a compelling and much needed alternative to existing options in the swimwear market.

Hubble Contacts

Series A in 2017
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.

Hubble Contacts

Series A in 2017
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.